ASCENTRA-UC expected to enroll up to 204 patients with moderately to severely active ulcerative coli

ASCENTRA-UC expected to enroll up to 204 patients with moderately to severely active ulcerative coli

Presentation to highlight fibrostenotic Crohn's disease biology and the potential of a locally b

Stock futures rise on Wednesday, with Verra Mobility's shares plunging 45% after Avis Budget Gro

Palisade Bio (NASDAQ:PALI) reported quarterly losses of $(0.05) per share which missed the analyst c

Data demonstrate colon tissue PDE4/cAMP pathway modulation and sustained active metabolite exposure

Poster presentation scheduled for Tuesday, May 5th at 12:30 PM CDTDenver, CO, April 16, 2026 (GLOBE

Wolfe Research analyst Andy Chen initiates coverage on Palisade Bio (NASDAQ:PALI) with a Outperfo

PALI-2108 demonstrated favorable safety and tolerability with no serious adverse events after two we

HC Wainwright & Co. analyst Mitchell S. Kapoor initiates coverage on Palisade Bio (NASDAQ:PAL

Stifel analyst Alex Thompson initiates coverage on Palisade Bio (NASDAQ:PALI) with a Buy rating a

Phase 1b translational data demonstrate localized ileocolonic target engagement, suppression of infl

Palisade Bio, Inc. (Nasdaq: PALI) ("Palisade" or the "Company"), a clinical-stage bi

B. Riley Securities analyst William Woods initiates coverage on Palisade Bio (NASDAQ:PALI) with a

PALI-2108 is the first and only PDE4 inhibitor in development designed for targeted delivery to the

Clear Street analyst Kaveri Pohlman initiates coverage on Palisade Bio (NASDAQ:PALI) with a Buy r

PALI-2108 is the first and only PDE4 inhibitor in development targetingthe terminal ileum and colon

Piper Sandler analyst Yasmeen Rahimi initiates coverage on Palisade Bio (NASDAQ:PALI) with a Over

Palisade Bio (NASDAQ:PALI) reported quarterly losses of $(0.38) per share which missed the analyst c

First dual-acting anti-inflammatory and anti-fibrotic candidate in development for FSCD, a condition

PALI-2108 is the first and only PDE4 inhibitor designed to target terminal ileum and colon for fibro

Steven Cohen's Point72 Asset Management has doubled the S&P 500's three-year return and

Palisade Bio, Inc.  (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage bi

PALI-2108 demonstrated favorable safety, with no serious adverse events, lab abnormalities, or EKG c

First dual-acting anti-inflammatory and anti-fibrotic candidate in development for FSCD, a condition

PALI-2108 demonstrated to be safe and well tolerated with no serious adverse events (SAEs)Extended h

PALI-2108 is the first and only PDE4 inhibitor designed to target terminal ileum and colon for fibro

Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage bio

Brookline Capital analyst Kumaraguru Raja maintains Palisade Bio (NASDAQ:PALI) with a Buy and mai

Palisade Bio (NASDAQ:PALI) reported quarterly losses of $(0.47) per share which beat the analyst con

Two posters presented at Digestive Disease Week (DDW) 2025Preclinical results indicate that PALI-210